Plus Therapeutics (PSTV) Competitors $0.42 -0.01 (-1.25%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PSTV vs. SPAI, LNSR, LAKE, INO, PROF, RCEL, LUCD, HYPR, PDEX, and OBIOShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Safe Pro Group (SPAI), LENSAR (LNSR), Lakeland Industries (LAKE), Inovio Pharmaceuticals (INO), Profound Medical (PROF), Avita Medical (RCEL), Lucid Diagnostics (LUCD), Hyperfine (HYPR), Pro-Dex (PDEX), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry. Plus Therapeutics vs. Its Competitors Safe Pro Group LENSAR Lakeland Industries Inovio Pharmaceuticals Profound Medical Avita Medical Lucid Diagnostics Hyperfine Pro-Dex Orchestra BioMed Plus Therapeutics (NASDAQ:PSTV) and Safe Pro Group (NASDAQ:SPAI) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings. Which has preferable valuation and earnings, PSTV or SPAI? Safe Pro Group has lower revenue, but higher earnings than Plus Therapeutics. Safe Pro Group is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$5.82M7.13-$12.98M-$2.24-0.19Safe Pro Group$2.17M63.06-$7.43M-$0.80-9.09 Is PSTV or SPAI more profitable? Plus Therapeutics has a net margin of -357.85% compared to Safe Pro Group's net margin of -731.46%. Plus Therapeutics' return on equity of 0.00% beat Safe Pro Group's return on equity.Company Net Margins Return on Equity Return on Assets Plus Therapeutics-357.85% N/A -117.72% Safe Pro Group -731.46%-328.85%-248.09% Do analysts prefer PSTV or SPAI? Plus Therapeutics presently has a consensus target price of $7.88, suggesting a potential upside of 1,783.97%. Safe Pro Group has a consensus target price of $10.50, suggesting a potential upside of 44.33%. Given Plus Therapeutics' higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than Safe Pro Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Safe Pro Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Do institutionals & insiders hold more shares of PSTV or SPAI? 3.3% of Plus Therapeutics shares are owned by institutional investors. 0.8% of Plus Therapeutics shares are owned by company insiders. Comparatively, 54.8% of Safe Pro Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor PSTV or SPAI? In the previous week, Plus Therapeutics had 5 more articles in the media than Safe Pro Group. MarketBeat recorded 10 mentions for Plus Therapeutics and 5 mentions for Safe Pro Group. Safe Pro Group's average media sentiment score of 1.22 beat Plus Therapeutics' score of -0.14 indicating that Safe Pro Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Safe Pro Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPlus Therapeutics beats Safe Pro Group on 9 of the 16 factors compared between the two stocks. Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.49M$2.55B$5.77B$10.50BDividend YieldN/A55.05%5.61%4.58%P/E Ratio-0.1923.44345.8827.02Price / Sales7.13712.79554.61127.73Price / CashN/A27.8326.0131.15Price / Book-0.285.4013.846.53Net Income-$12.98M$32.95M$3.29B$271.67M7 Day Performance-1.67%4.58%197.68%3.88%1 Month Performance-13.94%5.78%182.78%8.75%1 Year Performance-73.71%2.25%329.19%26.99% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics3.2016 of 5 stars$0.42-1.3%$7.88+1,784.0%-74.2%$41.49M$5.82M-0.1920News CoverageSPAISafe Pro Group3.3164 of 5 stars$7.41-6.8%$10.50+41.7%+136.5%$149.56M$2.17M-9.2611Positive NewsUpcoming EarningsLNSRLENSAR0.7718 of 5 stars$12.34-1.0%$15.00+21.6%+185.6%$148.83M$53.49M-2.93110News CoveragePositive NewsLAKELakeland Industries4.8708 of 5 stars$14.49-1.0%$25.00+72.5%-26.1%$140.02M$167.21M-5.292,100Positive NewsINOInovio Pharmaceuticals3.7819 of 5 stars$2.28-4.2%$8.80+286.0%-61.6%$126.48M$220K-0.87320PROFProfound Medical1.7474 of 5 stars$4.09+1.2%$11.00+168.9%-44.9%$121.69M$10.68M-2.80150News CoveragePositive NewsRCELAvita Medical2.4255 of 5 stars$6.76+48.2%$11.60+71.6%-45.5%$121.38M$64.25M-3.43130High Trading VolumeLUCDLucid Diagnostics2.7843 of 5 stars$1.06+2.9%$3.65+244.3%+30.9%$111.73M$4.35M-0.8970Analyst DowngradeHYPRHyperfine0.9864 of 5 stars$1.39-2.1%$1.28-7.7%+41.9%$111.58M$12.89M-2.67190PDEXPro-Dex2.4173 of 5 stars$32.62-1.4%$56.00+71.7%+28.6%$107.87M$66.59M12.08140OBIOOrchestra BioMed3.0379 of 5 stars$2.60+1.2%$13.50+419.2%-50.3%$99.31M$2.64M-1.424Positive News Related Companies and Tools Related Companies Safe Pro Group Competitors LENSAR Competitors Lakeland Industries Competitors Inovio Pharmaceuticals Competitors Profound Medical Competitors Avita Medical Competitors Lucid Diagnostics Competitors Hyperfine Competitors Pro-Dex Competitors Orchestra BioMed Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSTV) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PSTV Stock Alerts